Ken Griffin Kazia Therapeutics LTD Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
17Shares Held
1.77MCall Options Held
24KPut Options Held
0-
Mai Capital Management1.36MShares$7.83 Million0.01% of portfolio
-
Morgan Stanley New York, NY201KShares$1.15 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$238,0830.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$225,4490.0% of portfolio
-
Jpmorgan Chase & CO New York, NY37.8KShares$217,1210.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $86.7M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...